SWOG 1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Dr. Charles Kuzma
Men and women ages 18 and older, diagnosed with advanced or metastatic cancer of the esophagus, stomach, or gastroesophageal junction (GEJ). For additional criteria, call the Research Coordinator or visit the study weblink.
Southwest Oncology Group
Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells.
This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.